Myositis Clinical Trials

8 recruiting

Myositis Trials at a Glance

54 actively recruiting trials for myositis are listed on ClinicalTrialsFinder across 6 cities in 37 countries. The largest study group is Phase 1 with 11 trials, with the heaviest enrollment activity in Boston, Paris, and Bethesda. Lead sponsors running myositis studies include Chongqing Precision Biotech Co., Ltd, Assistance Publique - Hôpitaux de Paris, and National Institute of Environmental Health Sciences (NIEHS).

Browse myositis trials by phase

Treatments under study

About Myositis Clinical Trials

Looking for clinical trials for Myositis? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myositis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myositis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting
Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Dermatomyositis (DM)Juvenile Dermatomyositis (JDM)
National Institute of Environmental Health Sciences (NIEHS)300 enrolled1 locationNCT07111065
Recruiting

Environmental Risk Factors for the Anti-synthetase Syndrome

DermatomyositisPolymyositisMyositis+2 more
National Institute of Environmental Health Sciences (NIEHS)580 enrolled8 locationsNCT01276470
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting

Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis

Autoinflammatory DiseaseJuvenile Dermatomyositis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)5,000 enrolled1 locationNCT00059748
Recruiting

Adult and Juvenile Myositis

DermatomyositisInclusion Body MyositisPolymyositis
National Institute of Environmental Health Sciences (NIEHS)1,200 enrolled4 locationsNCT00017914
Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory Myopathy
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Not Applicable

Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusDermatomyositis+1 more
The First Affiliated Hospital with Nanjing Medical University72 enrolled1 locationNCT07558850
Recruiting
Phase 2Phase 3

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

Idiopathic Inflammatory Myositis (IIM)DERMATOMYOSITIS OR POLYMYOSITIS
Restem, LLC.40 enrolled2 locationsNCT07160205
Recruiting
Phase 3

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

Myositis
Pfizer318 enrolled147 locationsNCT05895786
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Polymyositis, Dermatomyositis
AstraZeneca240 enrolled234 locationsNCT06455449
Recruiting
Phase 1

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

DermatomyositisPolymyositis
Pfizer211 enrolled24 locationsNCT06698796
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting

Muscle Health Measurements Using Electrical Impedance Myography

Muscular DystrophiesMyositisCongenital Myopathy+4 more
Beth Israel Deaconess Medical Center150 enrolled1 locationNCT07502989
Recruiting

Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

Dermatomyositis
University of Pennsylvania300 enrolled1 locationNCT02945345
Recruiting

Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases

Inflammatory Bowel DiseasesSclerodermaVasculitis+2 more
University Hospital, Toulouse3,000 enrolled1 locationNCT05251415
Recruiting
Not Applicable

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Myasthenia GravisAmyotrophic Lateral SclerosisNeuromuscular Diseases (NMD)+15 more
University of Missouri-Columbia50 enrolled1 locationNCT07478172
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting

Comparison between the Camry and the Jamar Dynamometers in measuring hand grip strength in people with Inclusion Body Myositis

Inclusion Body Myositis
Murdoch University50 enrolled1 locationACTRN12626000086369
Recruiting
Not Applicable

RCT of Tocilizumab for Anti-MDA5+DM

Dermatomyositis
Peking Union Medical College Hospital110 enrolled1 locationNCT07377058